Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Argentum Pharmaceuticals can’t have a Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.
Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
The US Court of Appeals for the Federal Circuit has affirmed a lower court’s decision which found that Banner Life Sciences wasn’t infringing a Biogen patent with its bioequivalent version of a multiple sclerosis drug.
Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.
An association representing Indian cancer patients has asked the country’s government to cancel Gilead Sciences’ patents on remdesivir, the experimental antiviral which is hoped can be used to treat coronavirus.
Notorious ‘pharma bro’ Martin Shkreli and his former drug company Retrophin want antitrust claims filed against them in federal court dismissed.
The Biotechnology Innovation Organization has converted its 2020 international convention into an entirely online experience, BIO Digital.
Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.
A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.